000824545 001__ 824545
000824545 005__ 20210129225050.0
000824545 0247_ $$2doi$$a10.1007/s00259-016-3360-2
000824545 0247_ $$2ISSN$$a0340-6997
000824545 0247_ $$2ISSN$$a1432-105X
000824545 0247_ $$2ISSN$$a1619-7070
000824545 0247_ $$2ISSN$$a1619-7089
000824545 0247_ $$2WOS$$aWOS:000389242200013
000824545 0247_ $$2altmetric$$aaltmetric:6260303
000824545 0247_ $$2pmid$$apmid:26996777
000824545 037__ $$aFZJ-2016-07117
000824545 082__ $$a610
000824545 1001_ $$0P:(DE-HGF)0$$aSawicki, Lino M.$$b0$$eCorresponding author
000824545 245__ $$aDiagnostic potential of PET/CT using a $^{68}$Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience
000824545 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2017
000824545 3367_ $$2DRIVER$$aarticle
000824545 3367_ $$2DataCite$$aOutput Types/Journal article
000824545 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1482130370_5861
000824545 3367_ $$2BibTeX$$aARTICLE
000824545 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000824545 3367_ $$00$$2EndNote$$aJournal Article
000824545 520__ $$aPurpose To evaluate the diagnostic potential of whole-bodyPET/CT using a 68Ga-labelled PSMA ligand in renal cell carcinoma(RCC).Methods Six patients with histopathologically proven RCCunderwent 68Ga-PSMA PET/CT. Each PET/CT scan wasevaluated in relation to lesion count, location and dignity.SUVmax was measured in primary tumours and PETpositivemetastases. Tumour-to-background SUVmax ratios(TBRSUVmax) were calculated for primary RCCs in relationto the surrounding normal renal parenchyma. Metastasis-tobackgroundSUVmax ratios (MBRSUVmax) were calculatedfor PET-positive metastases in relation to gluteal muscle.Results Five primary RCCs and 16 metastases were evaluated.The mean SUVmax of the primary RCCs was 9.9 ± 9.2(range 1.7 – 27.2). Due to high uptake in the surrounding renalparenchyma, the mean TBRSUVmax of the primary RCCs wasonly 0.2 ± 0.3 (range 0.02 – 0.7). Eight metastases showed focal68Ga-PSMA uptake (SUVmax 9.9 ± 8.3, range 3.4 – 25.6).The mean MBRSUVmax of these PET-positive metastases was11.7 ± 0.2 (range 4.4 – 28.1). All PET-negative metastaseswere subcentimetre lung metastases.Conclusion 68Ga-PSMA PET/CT appears to be a promisingmethod for detecting RCC metastases. However, no additionaldiagnostic value in assessing the primary tumour was found.
000824545 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000824545 588__ $$aDataset connected to CrossRef
000824545 7001_ $$0P:(DE-HGF)0$$aBuchbender, Christian$$b1
000824545 7001_ $$0P:(DE-HGF)0$$aBoos, Johannes$$b2
000824545 7001_ $$0P:(DE-HGF)0$$aGiessing, Markus$$b3
000824545 7001_ $$0P:(DE-Juel1)131818$$aErmert, Johannes$$b4$$ufzj
000824545 7001_ $$0P:(DE-HGF)0$$aAntke, Christina$$b5
000824545 7001_ $$0P:(DE-HGF)0$$aAntoch, Gerald$$b6
000824545 7001_ $$0P:(DE-Juel1)132313$$aHautzel, Hubertus$$b7$$ufzj
000824545 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-016-3360-2$$gVol. 44, no. 1, p. 102 - 107$$n1$$p102 - 107$$tEuropean journal of nuclear medicine and molecular imaging$$v44$$x1619-7089$$y2017
000824545 8564_ $$uhttps://juser.fz-juelich.de/record/824545/files/art_10.1007_s00259-016-3360-2.pdf$$yRestricted
000824545 8564_ $$uhttps://juser.fz-juelich.de/record/824545/files/art_10.1007_s00259-016-3360-2.gif?subformat=icon$$xicon$$yRestricted
000824545 8564_ $$uhttps://juser.fz-juelich.de/record/824545/files/art_10.1007_s00259-016-3360-2.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000824545 8564_ $$uhttps://juser.fz-juelich.de/record/824545/files/art_10.1007_s00259-016-3360-2.jpg?subformat=icon-180$$xicon-180$$yRestricted
000824545 8564_ $$uhttps://juser.fz-juelich.de/record/824545/files/art_10.1007_s00259-016-3360-2.jpg?subformat=icon-640$$xicon-640$$yRestricted
000824545 8564_ $$uhttps://juser.fz-juelich.de/record/824545/files/art_10.1007_s00259-016-3360-2.pdf?subformat=pdfa$$xpdfa$$yRestricted
000824545 909CO $$ooai:juser.fz-juelich.de:824545$$pVDB
000824545 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000824545 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000824545 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000824545 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000824545 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000824545 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2015
000824545 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000824545 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000824545 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000824545 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000824545 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000824545 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000824545 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2015
000824545 9141_ $$y2017
000824545 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131818$$aForschungszentrum Jülich$$b4$$kFZJ
000824545 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132313$$aForschungszentrum Jülich$$b7$$kFZJ
000824545 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000824545 920__ $$lyes
000824545 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000824545 9201_ $$0I:(DE-Juel1)VDB145$$kKME$$lKlinisch-Medizinische Einrichtungen (Univ. Düsseldorf)$$x1
000824545 980__ $$ajournal
000824545 980__ $$aVDB
000824545 980__ $$aI:(DE-Juel1)INM-5-20090406
000824545 980__ $$aI:(DE-Juel1)VDB145
000824545 980__ $$aUNRESTRICTED
000824545 981__ $$aI:(DE-Juel1)VDB145